GMAB or TECH Which Is the Better Value Stock Right Now?
| GMAB Stock | USD 19.42 1.18 5.73% |
About 61% of Genmab AS's investor base is looking to short. The analysis of the overall investor sentiment regarding Genmab AS suggests that many traders are alarmed. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.
GMAB vs. TECH Which Stock Is the Better Value Option
Read at zacks.com
 |
Genmab AS Fundamental Analysis
We analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Genmab AS is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Genmab AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS stock to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
Peers
Genmab AS Related Equities
| PCVX | Vaxcyte | 8.45 | ||||
| DAWN | Day One | 7.30 | ||||
| ALEC | Alector | 1.96 | ||||
| AKRO | Akero Therapeutics | 1.83 | ||||
| LEGN | Legend Biotech | 1.81 | ||||
| EWTX | Edgewise Therapeutics | 1.24 | ||||
| TVTX | Travere Therapeutics | 1.04 | ||||
| BPMC | Blueprint Medicines | 0.65 | ||||
| TERN | Terns Pharmaceuticals | 0.99 | ||||
| ASND | Ascendis Pharma | 1.14 | ||||
| CYTK | Cytokinetics | 2.74 | ||||
| APLS | Apellis Pharmaceuticals | 5.91 | ||||
| AMLX | Amylyx Pharmaceuticals | 5.95 |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |